Skip to main content
59°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Theralase Technologies Inc
(TSV:
TLT
)
0.2100
+0.0200 (+10.53%)
Streaming Delayed Price
Updated: 3:53 PM EDT, May 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Theralase Technologies Inc
< Previous
1
2
3
Next >
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
Today 16:30 EDT
This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025)...
Via
Newsfile
Theralase to Present Groundbreaking Research at ASTRO 2025
May 28, 2025
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase Provides Corporate Update
May 20, 2025
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
May 05, 2025
Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
February 13, 2025
Via
ACCESS Newswire
Theralase(R) Launches New Clinical Study Site in Canada
December 05, 2024
Via
ACCESSWIRE
Theralase Discovers New Mechanism of Action of Lead Drug
April 28, 2025
Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase(R) Closes Non-Brokered Private Placement
April 14, 2025
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
April 10, 2025
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...
Via
Newsfile
Ruvidar Demonstrates 7 Year Complete Response
April 07, 2025
Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical...
Via
Newsfile
Ruvidar Effective in the Treatment of Herpes
March 24, 2025
Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase(R) Releases 2024 Annual Financial Statements
March 12, 2025
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase(R) Closes Non-Brokered Private Placement
March 11, 2025
Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
March 10, 2025
Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...
Via
Newsfile
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
February 25, 2025
Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...
Via
Newsfile
Topics
Death
Exposures
Death
Theralase(R) Demonstrates Effective Treatment of Herpes
February 12, 2025
Via
ACCESS Newswire
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
February 10, 2025
Via
ACCESS Newswire
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
January 27, 2025
Via
ACCESS Newswire
Theralase(R) Launches Three New Clinical Study Sites in USA
December 09, 2024
Via
ACCESSWIRE
Theralase(R) Release’s 3Q2024 Financial Statements
November 27, 2024
Via
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement
November 15, 2024
Via
ACCESSWIRE
Theralase(R) Extends Warrants
November 12, 2024
Via
ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 07, 2024
Via
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
September 24, 2024
Via
ACCESSWIRE
Theralase(R) Extends Warrants
September 19, 2024
Via
ACCESSWIRE
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
September 03, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
August 28, 2024
Via
ACCESSWIRE
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
August 21, 2024
Via
ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
August 12, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
July 08, 2024
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
